Victory Capital Management
GRCL

Victory Capital Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Victory Capital Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59,910
Closed -$362K – 2838
2021
Q4 		$362K Sell
59,910
-2,650
-4% -$25.5K ﹤0.01% 2317
2021
Q3 		$868K Sell
62,560
-670
-1% -$7.91K ﹤0.01% 1923
2021
Q2 		$822K Sell
63,230
-3,620
-5% -$48.5K ﹤0.01% 1963
2021
Q1 		$1.03M Buy
+66,850
New +$1.58M ﹤0.01% 1902

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Victory Capital Management's GRCL Position: Q1 2022 in Review

Victory Capital Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2022, closing a stake of 59,910 shares — an estimated $362K sold.

Victory Capital Management first reported a position in GRCL in Q1 2021 and held it in 4 quarters. The position peaked at $1.03M in Q1 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q1 2022.

  • Victory Capital Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Victory Capital Management sold 59,910 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2022, an estimated $362K.
  • Victory Capital Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 4 quarters.
  • Victory Capital Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1.03M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2022.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.